Aim: To examine the clinical effect of four antidementia drugs (donepezil, galantamine, rivastigmine and memantine) in Alzheimer's disease patients who were divided into subgroups based on their periventricular hyperintensity (PVH) severity.
Introduction
As a result of a rapidly aging world population, dementia has become a significant social priority. Alzheimer's disease (AD) is the most common cause of dementia, and is a neurodegenerative disease characterized by the presence of amyloid-beta (Aβ) plaques with neuritic plaques and neurofibrillary tangles that add to the severity of these changes. 1 White matter lesions (WML), including periventricular hyperintensity (PVH) and deep white matter hyperintensity (DWMH), are visualized as an increased signal on T2-weighted and fluid-attenuated inversion recovery magnetic resonance imaging sequences, and are observed in normal older adults as well as in AD patients. 2 In a previous report, WML were associated with clinical risk and a symptomatic course of AD. 3 The volume of PVH was also associated with neurofibrillary tangles, and the volume of DWMH was associated with diffuse plaques, showing that AD pathology could contribute to the vascular or white matter pathology. 4 Notably, our previous studies showed that the severity of WML was closely related to AD pathology, and strongly influenced the deterioration of cognitive and affective functions in AD patients. 5, 6 Early-stage AD patients might be more vulnerable to the cognitive effect of WHL than cognitively normal older adults with a similar burden of WHL. 7 Although there has been much debate about the relationship between AD pathology and WML, there is no report on the WML-dependent effectiveness of drugs on AD patients. In the present study, therefore, we examined the clinical effect of four antidementia drugs (donepezil, galantamine, rivastigmine and memantine) in AD patients who were divided into subgroups based on their PVH severity.
Methods

Participants and study design
This was a retrospective clinical cohort study carried out in the outpatient clinic of Okayama University Hospital, Okayama, Japan, and affiliated hospitals from June 2011 to March 2016. For the present study, we recruited 551 AD patients (201 men and 350 women; aged 78.4 ± 7.3 years) that were receiving monotherapy with donepezil, galantamine, rivastigmine or memantine. All patients were prescribed anti-AD drugs for the first time. Those patients that were receiving combination therapy or that switched to a combination therapy of cholinesterase inhibitor plus memantine were excluded from the present study. AD patients were diagnosed with probable or possible AD according to the National Institute of Neurological and Communicative Disorders and Stroke AD and Related Disorders Association. Magnetic resonance imaging was used to estimate changes in white matter (WM) with PVH using the Fazekas scale 8 on T2-weighted images (T2WI) and fluid attenuated inversion recovery images, and were divided into four subgroups according to the grade of PVH (0-III). Furthermore, parahippocampal gyrus atrophy of each PVH group was evaluated using the Z-score of the voxel-based specific regional analysis system for AD (VSRAD), 9 which become an indicator reflecting the degree of the entorhinal cortex for diagnosis of early AD. 10 The drug dose was gradually increased as follows: donepezil, from 3 to 5 or 10 mg; galantamine, from 8 to 16 or 24 mg over 4 or 8 weeks; rivastigmine, from 4.5 to 18 mg over 16 weeks; and memantine, from 5 to 20 mg over 4 weeks. Cognitive functions were assessed using the Mini-Mental State Examination (MMSE) and Hasegawa Dementia Scale-Revised (HDS-R). The behavioral and psychological symptoms of dementia were assessed using the 15-item Geriatric Depression Scale (GDS) for depression, the Apathy Scale (AS) for apathy and Abe's Behavioral and Psychological Symptoms of Dementia score (ABS). 11 In addition, the activities of daily living (ADL) were assessed using the Alzheimer's Disease Cooperative Study-ADL. These scores were assessed at the baseline, and at 3, 6 and 12 months after initiation (12 months as a whole).
Ethical permission for this study was provided by the Ethics Committee on Epidemiological Studies of the Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences (approval #775), and written informed consent was obtained from all participants before enrollment.
Statistical analysis
Demographic and clinical data are presented as mean ± SD in the text and tables. Statistical analyses were carried out using statistical software (SPSS 22.0.0.0; IBM, Armonk, New York, USA). Differences in the distribution of demographic factors among PVH grades (0-III) were analyzed using the χ 2 -test and Jonckheere-Terpstra's test. After having checked for normality, baseline age, Z-scores of 
Results
Participants' characteristics
The baseline demographic and clinical features of all AD patients (n = 551) and each group according to the grade of PVH (0-III) are shown in Table 1 . The ratio of women among the 551 AD patients was 63.5%, and the average age of all AD patients was 78.4 ± 7.3 years (mean ± SD). The number of patients in each PVH groups was as follows: PVH 0, n = 41; PVH I, n = 212; PVH II, n = 179; PVH III, n = 119. Although there were no differences in the gender ratio, Z-score of VSRAD, emotional scores (GDS, AS, ABS) or ADL in the four PVH subgroups, the baseline age showed a WM severity-dependent increase: 72.2 ± 8.1 years for PVH 0, 77.5 ± 6.8 years for PVH I, 79.6 ± 6.7 years for PVH II and 80.5 ± 7.4 years for PVH III (**P < 0.01 vs PVH 0, ## P < 0.01 vs PVH I and P-value for increasing trend <0.001). In contrast, cognitive scores showed a WM severity-dependent decrease in MMSE ( Table 2 shows the change of each drug dosage (mg/day) from 3 to 12 months, and baseline PVH severitydependent features of AD patients in the four drug subgroups. The average drug dosage showed a progressive increase from 3 to 12 months in all four drugs (Table 2, top). Finally, 249 patients dropped out or were lost to follow up, and 302 patients remained. The number of patients in each drug subgroup is shown in Table 2 (the digit in parentheses shows the number of patients in each term). In the PVH 0 subgroup (n = 41), the rivastigmine group showed a higher baseline ABS (12.3 ± 10.0) than the donepezil group (2.1 ± 3.1, *P < 0.05). In the PVH I subgroup (n = 212), the memantine group showed a higher baseline ABS (9.8 ± 6.9) than the donepezil group (2.8 ± 3.9, *P < 0.05) and the galantamine group (3.2 ± 4.4, # P < 0.05). In the PVH II subgroup (n = 179), the Figure 2 The mean changes of clinical scores in each drug (donepezil, galantamine, rivastigmine and memantine) from the baseline (0 months [M] ) to 3, 6, 9 and 12 M in the periventricular hyperintensity (PVH) I subgroup. The Apathy Scale (AS) showed improvements from the baseline in response to memantine at 3 and 9 M ( ¶ memantine group (12.0 ± 9.3) again showed a higher baseline ABS (12.0 ± 9.3) than the donepezil group (3.1 ± 5.4, *P < 0.05). There were no significant differences in the baseline age and other baseline scores.
Changes from the baseline after the therapy Figures 1-4 summarize the mean changes of each drug from the baseline (0 months) to 3, 6, 9 and 12 months in PVH 0-III. The data of memantine was omitted from Figure 1 because there were just two cases ( Table 2) . As shown in Figure 1 , the PVH 0 subgroup preserved cognitive MMSE and HDS-R, affective GDS, AS, ABS, and ADL until 12 months of each drug treatment. An interdrug comparison showed that MMSE was better preserved in the galantamine group (1.1 ± 4.0, *P < 0.05 vs donepezil) than in the donepezil group (À1.2 ± 1.9) at 9 months, whereas GDS was better preserved in the galantamine group (À0.8 ± 3.9) than in the rivastigmine group (1.2 ± 1.6, # P < 0.05 vs galantamine) at 9 months. Figure 2 also shows the preservation of cognitive MMSE and HDS-R, and affective GDS and ABS until 12 months in the PVH I subgroup. AS showed an improvement from the baseline in the memantine group at 3 months (À9.0 ± 10.8, ¶ P < 0.05) and 9 months (À4.2 ± 5.9, ¶ P < 0.05) and in the galantamine group at 9 months (À2.5 ± 6.7, § § P < 0.01). The donepezil group worsened in AS at 9 months from the baseline (4.3 ± 10.0, † P < 0.05). ADL worsened in the galantamine group (À0.9 ± 4.0, § P < 0.05) at 12 months. The interdrug comparison showed an improvement of ABS in the memantine group (À5.4 ± 4.2, *P < 0.05 vs donepezil) than in the donepezil group (0.4 ± 2.6) at 9 months. Figure 3 shows well preserved affective GDS, AS and ABS until 12 months in the PVH II subgroup. MMSE showed a significant improvement from the baseline in the galantamine group (1.5 ± 2.2, § P < 0.05) at 9 months and HDS-R (0.4 ± 3.7, § P < 0.05) at 3 months. However, the galantamine group showed a significant decline of ADL (À1.8 ± 2.6, § P < 0.05) at 12 months. The interdrug comparison showed better preservation of MMSE in the galantamine group (1.5 ± 2.2, **P < 0.01 vs donepezil) than in the donepezil group (À2.8 ± 2.4) at 9 months.
As shown in Figure 4 , the PVH III subgroup showed well preserved MMSE, HDS-R, GDS, AS and ABS until 12 months. ADL deteriorated in the riverstigmine group at 6 months (À3.3 ± 2.5, ‡ P < 0.05) and 12 M (À3.3 ± 2.7, ‡ P < 0.05). The interdrug comparison showed better preservation of HDS-R in the rivastigmine group (0.5 ± 4.5, **P < 0.01 vs donepezil) and the galantamine group (À0.5 ± 5.4, *P < 0.05 vs donepezil) than in the donepezil group (À4.1 ± 4.6).
Discussion
In the present study, we evaluated the clinical features of AD patients who were divided into four subgroups according to the PVH grade (0-III). The baseline age became higher with PVH grades (Table 1) , and cognitive scores (MMSE and HDS-R) showed a WM severity-dependent decrease ( Table 1 ). The ABS baseline of the rivastigmine group (PVH 0) and the memantine group (PVH I-II) was significantly higher than that of the donepezil group, whereas that of the memantine group was significantly higher than that of the galantamine group (Table 2) . However, there were no significant differences in the baseline age and other baseline scores among the four drug groups ( Table 2 ). The PVH 0 subgroup showed preserved cognitive, affective, and ADL functions until 12 months in all four drug groups. After treatment with memantine and galantamine, AS improved significantly from the baseline in the PVH I subgroup, whereas galantamine showed a worse ADL from the baseline (Fig. 2) . In the PVH II subgroup, galantamine showed a significant improvement of cognitive scores (MMSE and HDS-R) from the baseline, but a worse ADL from the baseline (Fig. 3) . In the PVH III subgroup, MMSE, HDS-R, GDS, AS and ABS were well preserved in all four drug groups until 12 months, but (Fig. 4) .
Previous studies showed that WML, such as PVH and DWMH, reflect demyelination, loss of ependymal cells, arteriosclerosis and microinfarcts. PVH was associated with a loss of ventricular lining, and DWMH with deep WM demyelination. [12] [13] [14] The volume of PVH was also associated with neurofibrillary tangles, showing that the mechanism of AD might contribute to the vascular or white matter pathology. 4 Our previous studies showed that the severity of WML was closely related to a deterioration of the cognitive and affective functions in AD patients. 5, 6 Furthermore, PVH was related to a decline in cognitive function 15 and mental processing speed. 16 In the present study, cognitive scores (MMSE and HDS-R) showed a WM severity-dependent decrease with aging ( Table 1 ), suggesting that a worse PVH might reflect progression of AD pathology.
The present study first described the clinical effect of four antidementia drugs on AD patients who were divided into four PVH severity-dependent subgroups. The positive effect of galantamine in the PVH I-II subgroups might be consistent with a previous report, where galantamine was effective on cognitive, affective and ADL functions of AD accompanied by cerebrovascular disease 17 with increasing vascular reactivity 18 and regional cerebral blood flow. 19 We have also previously reported that galantamine improved frontal lobe cognitive function in elderly AD patients, 20 and maintained or improved cognitive, affective and ADL functions in AD with asymptomatic lacunar infarction. 21 There are several reports that showed that donepezil was effective for both positive and negative affective symptoms. [22] [23] [24] However, the present results showed that AS deteriorated at 9 months in the PVH I subgroup (Fig. 2) . Similarly, rivastigmine was reported to be effective for cognitive and ADL functions in severe AD patients. 25 However, the present results showed a deterioration of ADL at 6 and 12 months in the PVH III subgroup (Fig. 4) . These discrepancies could be due to different severities of AD patients between previous studies and the present study, and our PVH severity-dependent analysis. Some reports showed significant effects of memantine in the cognitive Severe Impairment Battery and Alzheimer's Disease Cooperative Study-ADL for moderate to severe AD patients. 15, 26 In agreement with our previous results, the present study showed a significant improvement from the baseline in AS of the PVH I subgroup at 3 and 9 months (Fig. 2) . 27, 28 There were limitations to the present retrospective study. Considering the nature of AD treatment, the outcome of measurements would be evaluated in the longest observation time. In other words, different transient effects in one time-point seem to be difficult to evaluate.
In conclusion, the present study showed that cognitive scores (MMSE and HDS-R) showed WM severitydependent decreases with increasing age (Table 1) . Furthermore, the four drugs showed WM severity-dependent sensitivity when assessing the clinical effect of cognitive, affective and ADL functions.
